GlassScriptPhysician profile
Felix D Vilinsky
NPI 1720076805
$903.35
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2021: $65.74 · 2022: $90.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $194.10 | 2019-2022 | |
| Novo Nordisk INC | $155.65 | 2019 | |
| Pfizer INC. | $116.26 | 2019 | |
| Vivus LLC | $50.68 | 2019 | |
| Shire North American Group INC | $48.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.64 | 2019 | |
| Amgen INC. | $46.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.97 | 2019 | |
| Insulet Corporation | $34.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.06 | 2019 | |
| Astellas Pharma US INC | $20.01 | 2019 | |
| Hikma Pharmaceuticals USA | $18.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.13 | 2019 | |
| Mannkind Corporation | $16.87 | 2019 | |
| Sanofi Pasteur INC. | $14.98 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14.98 | 2019 | |
| Merck Sharp & Dohme LLC | $12.34 | 2019 | |
| Ibsa Pharma INC. | $12.05 | 2019 | |
| Valeritas, INC. | $11.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Vilinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.